约翰·N·因萨尔奖:褪黑素能否改善全膝关节置换术后的主观睡眠质量?一项随机安慰剂对照试验
该随机双盲安慰剂对照试验纳入172例因原发性膝骨关节炎行单侧全膝关节置换术的患者,随机接受5 mg褪黑素(n=86)或125 mg维生素C安慰剂(n=86)每晚服用6周。结果显示,褪黑素组与安慰剂组在术后6周和90天的匹兹堡睡眠质量指数(PSQI)评分均无差异,褪黑素也未改善患者报告结局指标,结论不支持全膝关节置换术后常规使用褪黑素。
要点
- 褪黑素组与安慰剂组术后6周PSQI评分无差异(10.2±4.2 vs 10.5±4.4,P=.66)。
- 术后90天PSQI评分两组仍无差异(8.1±4.1 vs 7.5±4.0,P=.43)。
- 睡眠质量差与术后6周和90天更差的患者报告结局相关,但褪黑素未改变此关联。
核心结论
- 外源性褪黑素未改善全膝关节置换术后6周或90天的主观睡眠质量或患者报告结局指标。
- 睡眠质量差与更差的患者报告功能和疼痛相关。
- 作者结论认为其结果不支持全膝关节置换术后常规使用褪黑素。
研究设计与样本
- 随机双盲安慰剂对照试验,共纳入172例因原发性膝骨关节炎行单侧全膝关节置换术的患者,随机分为褪黑素5 mg组(n=86)和维生素C安慰剂125 mg组(n=86),每晚服用6周。
- 主要结局为术后6周和90天的匹兹堡睡眠质量指数(PSQI);次要结局包括6周和90天的患者报告结局指标、处方吗啡毫克当量、用药依从性、不良事件和90天再入院率。
主要发现
- 两组平均PSQI评分在术后6周均恶化,至90天恢复至术前基线水平。
- 褪黑素组与安慰剂组术后6周PSQI评分无差异(10.2±4.2 vs 10.5±4.4,P=.66)。
- 褪黑素组与安慰剂组术后90天PSQI评分无差异(8.1±4.1 vs 7.5±4.0,P=.43)。
- 褪黑素未改善术后6周或90天的膝关节损伤与骨关节炎结局评分-关节置换版、下肢活动量表、疼痛视觉模拟评分、退伍军人兰德12项躯体成分评分或心理成分评分。
- 单变量和多变量分析显示睡眠质量差与术后6周和90天更差的患者报告结局指标相关,但褪黑素未改变这些关联;两组在处方吗啡毫克当量、用药依从性、不良事件或90天再入院率方面无差异。
关键数值与推荐
- 主要结局PSQI评分在褪黑素组与安慰剂组术后6周分别为10.2±4.2和10.5±4.4(P=.66),术后90天分别为8.1±4.1和7.5±4.0(P=.43)。
- 两组在处方吗啡毫克当量、用药依从性、不良事件或90天再入院率方面无差异。
临床怎么用
- 作者结论认为其结果不支持全膝关节置换术后常规使用褪黑素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sleep disturbance is a common problem following total knee arthroplasty (TKA). The objective of this study was to determine if exogenous melatonin improves sleep quality following primary TKA. METHODS: A randomized, double-blind, placebo-controlled trial was conducted. A total of 172 patients undergoing unilateral TKA for primary knee osteoarthritis were randomized to receive either 5 mg melatonin (n = 86) or 125 mg vitamin C placebo (n = 86) nightly for 6 weeks. The primary outcome was the Pittsburgh Sleep Quality Index (PSQI) at 6 weeks and 90 days postoperatively. Secondary outcomes included 6-week and 90-day patient-reported outcome measures (PROMs), morphine milligram equivalents prescribed, medication compliance, adverse events, and 90-day readmissions. RESULTS: Mean PSQI scores worsened at 6 weeks before returning to the preoperative baseline at 90 days in both groups. There were no differences in PSQI scores between melatonin and placebo groups at 6 weeks (10.2 ± 4.2 versus 10.5 ± 4.4, P = .66) or 90 days (8.1 ± 4.1 versus 7.5 ± 4.0, P = .43). Melatonin did not improve the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement, Lower Extremity Activity Scale, Visual Analog Scale for pain, or Veterans Rand 12 Physical Component Score or Mental Component Score at 6 weeks or 90 days. Poor sleep quality was associated with worse PROMs at 6 weeks and 90 days on univariate and multivariable analyses, but melatonin did not modify these associations. There were no differences in morphine milligram equivalents prescribed, medication compliances, adverse events, or 90-day readmissions between both groups. CONCLUSIONS: Exogenous melatonin did not improve subjective sleep quality or PROMs at 6 weeks or 90 days following TKA. Poor sleep quality was associated with worse patient-reported function and pain. Our results do not support the routine use of melatonin after TKA.
引用
- LeBrun DG, Grubel J, Ong J, et al. The John N. Insall Award: Does Melatonin Improve Subjective Sleep Quality After Total Knee Arthroplasty? A Randomized, Placebo-Controlled Trial. J Arthroplasty. 2024. PMID: 38237875. doi:10.1016/j.arth.2024.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。